Skip to main
CAPR
CAPR logo

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc. demonstrates a positive outlook as its therapy, deramiocel, has shown a favorable long-term benefit-risk profile and has been well tolerated with no new safety signals. The ongoing partnership is expected to extend the company's operational runway, facilitating preparations for potential commercial launches and manufacturing scale-up, particularly in Europe. Furthermore, the focus on DMD-cardiomyopathy enhances the de-risking of the company's biolytical application (BLA) submission plans, potentially expediting deramiocel's market entry and driving partner-driven pre-commercial activities.

Bears say

Capricor Therapeutics Inc. is experiencing challenges due to mixed clinical trial results, evidenced by the decline in Performance of the Upper Limb 2.0 (PUL 2.0) total score among patients treated with deramiocel compared to untreated individuals. The average annual decline for deramiocel-treated patients showed only a marginal reduction in disease progression, highlighting uncertainties about the long-term efficacy of the therapy. Additionally, concerns regarding the company's ability to secure adequate funding for ongoing clinical development may further hinder its progress and negatively impact future stock performance.

Capricor Therapeutics (CAPR) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.